NxStage Medical, Inc. (NASDAQ:NXTM) has been given an average recommendation of “Hold” by the ten analysts that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and eight have given a hold rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $30.00.
A number of research firms recently weighed in on NXTM. Leerink Swann lowered shares of NxStage Medical from an “outperform” rating to a “market perform” rating and upped their target price for the stock from $28.00 to $30.00 in a report on Tuesday, August 22nd. Zacks Investment Research lowered shares of NxStage Medical from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Canaccord Genuity reaffirmed a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a report on Tuesday, October 17th. Finally, Northland Securities reaffirmed a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a report on Wednesday, November 8th.
In other NxStage Medical news, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $25.73, for a total value of $90,055.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $27.56, for a total transaction of $27,560.00. The disclosure for this sale can be found here. In the last three months, insiders sold 12,300 shares of company stock valued at $331,126. Corporate insiders own 4.70% of the company’s stock.
NxStage Medical (NXTM) traded down $0.11 during trading on Friday, reaching $26.01. 601,325 shares of the company were exchanged, compared to its average volume of 801,294. NxStage Medical has a twelve month low of $20.45 and a twelve month high of $30.80.
ILLEGAL ACTIVITY WARNING: “NxStage Medical, Inc. (NXTM) Receives $30.00 Consensus PT from Analysts” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2017/12/11/nxstage-medical-inc-nxtm-receives-30-00-consensus-pt-from-analysts.html.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
What are top analysts saying about NxStage Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NxStage Medical Inc. and related companies.